Business
MediWound Strengthens European Presence of NexoBrid®
NexoBrid gained marketing approval in Switzerland; launch expected first quarter 2023 Launch in France expected in third quarter 2023 YAVNE, Israel, Dec. 20,
About this update from Mediwound Ltd.
[{"type":"text","content":"NexoBrid gained marketing approval in Switzerland; launch expected first quarter 2023 Launch in France expected in third quarter 2023 YAVNE, Israel, Dec. 20, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced the marketing approval of NexoBrid® in Switzerland. MediWound has signed an agreement with Triskel Integrated Services to market and distribute NexoBrid in Switzerland, with a launch planned for the first quarter of 2023. Triskel also holds the distribution rights of NexoBrid in France, where NexoBrid is expected to launch in the third quarter of 2023. “There is a high unmet need for non-surgical therapy to treat moderate-to-severe burn patients. The approval and expected launch of NexoBrid in Switzerland is another step on our journey to bring this breakthrough treatment to burn patients around the world,” said Ofer Gonen, Chief Executive Officer at MediWound. “We are pleased with the progress in Switzerland and look forward to NexoBrid’s pending reimbursement approval and launch in France, one of the most lucrative markets in Europe. We continue on our potential path towards becoming the leader in bio-therapeutic solutions for tissue repair and regeneration,” added Ofer Gonen. Tamara Da Silva, Chief Executive Officer at Triskel, stated: \"We are thrilled at this opportunity to bring NexoBrid to Switzerland and France. We believe that NexoBrid will play a major role in the future of burn care in these new markets. We are committed to bringing innovative and life changing therapies to patients in these countries and look forward to expanding our collaboration with MediWound.” About NexoBrid NexoBrid® (concentrate of proteolytic enzymes enriched in bromelain) is a topically administered biological product that enzymatically removes nonviable burn tissue, or eschar, in patients with deep partial and full-thickness thermal burns within four hours of application without harming viable tissue. NexoBrid is approved in 42 countries, in the European Union and other international markets, and is at registration-stage with the Food and Drug Administration (FDA) with a PDUFA target date set as of January 1, 2023. NexoBrid is supported by the U.S. Biomedical Advanced Research and Deve...